<?xml version="1.0" encoding="UTF-8"?>
<p id="Par47">The exclusion criteria are as follows:
 <list list-type="bullet">
  <list-item>
   <p id="Par48">Positive for the hepatitis B surface antigen, anti-hepatitis C antibody, or anti-human immunodeficiency virus antibody</p>
  </list-item>
  <list-item>
   <p id="Par49">Malignant neoplasm including hepatocellular carcinoma</p>
  </list-item>
  <list-item>
   <p id="Par50">AST &gt; 500 IU/L or ALT &gt; 300 IU/L</p>
  </list-item>
  <list-item>
   <p id="Par51">Portal vein thrombosis, hemochromatosis, autoimmune hepatitis, Wilson's disease, or alpha-1-antitrypsin deficiency</p>
  </list-item>
  <list-item>
   <p id="Par52">Pregnant or breastfeeding women or those who refuse to use or cannot use contraceptives</p>
  </list-item>
  <list-item>
   <p id="Par53">History of hypersensitivity to G-CSF injection</p>
  </list-item>
  <list-item>
   <p id="Par54">Hypovolemic shock due to gastrointestinal bleeding at the time of hospitalization, or in need of a transfusion of more than three units of packed red blood cells, or MDF elevated from &lt; 32 points to ≥ 32 points due to gastrointestinal bleeding</p>
  </list-item>
  <list-item>
   <p id="Par55">Sepsis or uncontrolled acute infection</p>
  </list-item>
  <list-item>
   <p id="Par56">Hepatic encephalopathy grade 3–4</p>
  </list-item>
  <list-item>
   <p id="Par57">Previous history treatment with corticosteroids or pentoxifylline within the past 3 months</p>
  </list-item>
  <list-item>
   <p id="Par58">Myeloblasts observed in peripheral blood</p>
  </list-item>
  <list-item>
   <p id="Par59">Severe comorbidities (type 1 hepatorenal syndrome or serum creatinine &gt; 2.5 mg/dL at the time of screening, heart failure, lung disease, mental illness, or acute pancreatitis)</p>
  </list-item>
  <list-item>
   <p id="Par60">Refusal to participate in the clinical trial</p>
  </list-item>
 </list>
</p>
